KP-7
The pre-workout your current
formula isn't.
Built around Kaempferia parviflora. Clinically dosed. Nothing hidden.
Join the waitlistWhat's in it.
| Ingredient | Dose | Function |
|---|---|---|
| Kaempferia parviflora extract (5% total PMFs) | 200mg | PDE5 inhibition and eNOS activation; drives nitric oxide production and vascular adaptation. |
| L-Citrulline | 4,000mg | Nitric oxide substrate; supports pump and aerobic endurance. |
| Betaine Anhydrous | 2,500mg | Cellular osmolyte; supports power output and endurance under load. |
| Caffeine Anhydrous | 200mg | CNS activation; delays perceived fatigue. |
| L-Theanine | 200mg | Focus modulation; attenuates caffeine edge without reducing drive. |
| Rhodiola rosea (3% rosavins / 1% salidroside) | 150mg | Adaptogenic fatigue resistance. |
| Bioperine (95% piperine) | 5mg | Bioavailability enhancement across the full formula. |
All doses per serving. No proprietary blends. Quantities are non-negotiable.
The compound.
Kaempferia parviflora is a rhizomatous plant native to Southeast Asia, pharmacologically classified as a PDE5 inhibitor. By attenuating phosphodiesterase-5 activity, KP extends the half-life of cyclic GMP within vascular smooth muscle, triggering endothelial nitric oxide synthase (eNOS) activation. The downstream result is sustained NO release, progressive vasodilation, and measurable improvements in peripheral blood flow under exercise load — without androgenic or stimulant-class side effects.
An 8-week randomised controlled trial conducted at Chiang Mai University assessed KP supplementation in resistance-trained males at 200mg/day. Subjects demonstrated statistically significant improvements in leg press and bench press 1RM versus placebo, alongside measurable increases in lean mass. Vascular adaptation — not stimulant augmentation — is the proposed mechanism. KP-7 uses the clinically studied dose, standardised to the same extract profile referenced in that trial.
Early access.
KP-7 launches in the UK later this year. Leave your email to be notified first.